Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin D Marchant

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Pediatrics|April 6, 2006
Effectiveness of Centers for Disease Control and Prevention recommendations for outcomes of acute otitis mediaHoward Bauchner, Colin D Marchant, Alice Bisbee, et al.
Human Vaccines|February 11, 2011
Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United StatesGary S Marshall, Colin D Marchant, Mark Blatter, et al.
The Pediatric Infectious Disease Journal|November 5, 2011
Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregiversSandra K Schumacher, Colin D Marchant, Anita M Loughlin, et al.
International Journal of Pediatric Otorhinolaryngology|March 7, 2002
Antimicrobial guidelines for the treatment of acute bacterial rhinosinusitis in immunocompetent childrenMichael D Poole, Michael R Jacobs, Jack B Anon, et al.
The Pediatric Infectious Disease Journal|December 26, 2009
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infantsColin D Marchant, Jacqueline M Miller, Gary S Marshall, et al.
The Pediatric Infectious Disease Journal|January 15, 2010
Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of ageGary S Marshall, Colin D Marchant, Mark Blatter, et al.
Vaccine|July 28, 2012
Biologically plausible and evidence-based risk intervals in immunization safety researchAli Rowhani-Rahbar, Nicola P Klein, Cornelia L Dekker, et al.
Pediatrics|June 1, 2011
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infantsKristina A Bryant, Gary S Marshall, Colin D Marchant, et al.
The Pediatric Infectious Disease Journal|June 29, 2006
The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibodyJay M Lieberman, Wendy R Williams, Jacqueline M Miller, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Pediatrics|April 6, 2006
Effectiveness of Centers for Disease Control and Prevention recommendations for outcomes of acute otitis mediaHoward Bauchner, Colin D Marchant, Alice Bisbee, et al.
Human Vaccines|February 11, 2011
Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United StatesGary S Marshall, Colin D Marchant, Mark Blatter, et al.
The Pediatric Infectious Disease Journal|November 5, 2011
Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregiversSandra K Schumacher, Colin D Marchant, Anita M Loughlin, et al.
International Journal of Pediatric Otorhinolaryngology|March 7, 2002
Antimicrobial guidelines for the treatment of acute bacterial rhinosinusitis in immunocompetent childrenMichael D Poole, Michael R Jacobs, Jack B Anon, et al.
The Pediatric Infectious Disease Journal|December 26, 2009
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infantsColin D Marchant, Jacqueline M Miller, Gary S Marshall, et al.
The Pediatric Infectious Disease Journal|January 15, 2010
Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of ageGary S Marshall, Colin D Marchant, Mark Blatter, et al.
Vaccine|July 28, 2012
Biologically plausible and evidence-based risk intervals in immunization safety researchAli Rowhani-Rahbar, Nicola P Klein, Cornelia L Dekker, et al.
Pediatrics|June 1, 2011
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infantsKristina A Bryant, Gary S Marshall, Colin D Marchant, et al.
The Pediatric Infectious Disease Journal|June 29, 2006
The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibodyJay M Lieberman, Wendy R Williams, Jacqueline M Miller, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Pageof 3